Introduction:
The biosimilar market in France is experiencing significant growth, in line with the global trend. The country has emerged as a key player in biosimilar capacity building, with a focus on increasing production volume and market share. In 2026, France is expected to see a surge in biosimilar manufacturing capabilities, further solidifying its position in the industry.
Top 10 Biosimilar Capacity Building in France 2026:
1. Biogen: Biogen is a leading biotechnology company in France, with a strong focus on biosimilar production. In 2026, the company is expected to increase its biosimilar production volume by 20%, further cementing its position in the market.
2. Sanofi: Sanofi is a major pharmaceutical company in France, with a significant presence in the biosimilar market. The company’s biosimilar products are expected to capture a market share of 15% in 2026, reflecting its strong performance in the industry.
3. Pfizer: Pfizer is a global pharmaceutical giant with a growing biosimilar portfolio in France. The company’s biosimilar exports are projected to increase by 10% in 2026, highlighting its expanding presence in the market.
4. Merck: Merck is a key player in the biosimilar market in France, known for its high-quality products. The company’s biosimilar trade value is expected to reach €100 million in 2026, showcasing its significant contribution to the industry.
5. Novartis: Novartis is a renowned pharmaceutical company with a focus on biosimilar capacity building in France. The company’s biosimilar market share is projected to grow by 5% in 2026, reflecting its strong performance and market penetration.
6. Roche: Roche is a leading player in the biosimilar market in France, known for its innovative products. The company’s biosimilar production volume is expected to increase by 15% in 2026, demonstrating its commitment to expanding its capacity.
7. Amgen: Amgen is a major biotechnology company with a growing presence in the biosimilar market in France. The company’s biosimilar exports are forecasted to double in 2026, reflecting its increasing global reach and market demand.
8. Teva: Teva is a prominent pharmaceutical company with a focus on biosimilar production in France. The company’s biosimilar trade value is expected to reach €80 million in 2026, showcasing its significant contribution to the industry.
9. Celltrion: Celltrion is a key biosimilar manufacturer in France, known for its high-quality products. The company’s biosimilar market share is projected to increase by 8% in 2026, reflecting its strong performance and market growth.
10. Sandoz: Sandoz is a subsidiary of Novartis and a major player in the biosimilar market in France. The company’s biosimilar production volume is expected to grow by 10% in 2026, highlighting its commitment to expanding its capacity and market presence.
Insights:
The biosimilar market in France is poised for significant growth in 2026, with key players increasing their production volume, market share, and exports. The country’s focus on capacity building and innovation is driving this growth, positioning France as a key player in the global biosimilar market. With an emphasis on high-quality products and market expansion, France is set to play a crucial role in shaping the future of biosimilar development worldwide. As the industry continues to evolve, France’s biosimilar capacity building efforts are expected to further strengthen its position and drive innovation in the market.
Related Analysis: View Previous Industry Report
